Last week, Novartis AG’s complement factor B inhibitor iptacopan scored an approval in paroxysmal nocturnal hemoglobinuria (PNH) under the name Fabhalta. Today it posted a different type of success, a clinical one, in the Phase III APPEAR-C3G in C3 glomerulopathy (C3G).
Novartis’s Fabhalta Hits In Glomerulopathy But How Hard?
So far, Novartis has only reported that its Phase III trial has succeeded and investors face a wait to find out just how good the drug is.
More from Clinical Trials
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from R&D
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.